NeuroMab™ Anti-Sp35 BBB Shuttle Antibody(NRZP-1022-ZP3034)

Figure 1: SDS-PAGE gel showing immunoprecipitation of Sp35 with mAbs 1A7 and 2F3.

Figure 2: FACS results showing that MAb 1A7 and 2F3 bind to COS-7 or 293 cells expressing Sp35, but not to control cells that do not express Sp35.

Figure 3: MAbs 1A7 and 2F3 protect DRG neurons from myelin-mediated inhibition of neurite outgrowth.

Figure 4: Immunohistochemical staining ("IHC") of co-cultures of DRG neurons and oligodendrocytes treated with monoclonal antibodies 1A7 and 2F3 or a control antibody.

Panels D and E are enlargements of panels B and C, respectively. Staining with anti-βIII-tubulin antibody to identity axons, or anti-MBP antibody to identify oligodendrocytes. F: Quantitation of MBP+ myelinating cells upon treatment of cocultures with 1A7 or 2F3. G: Western blot analysis to quantify the MBP produced from cocultures of DRG neurons and oligodendrocytes treated with monoclonal antibodies 1A7 and 2F3.

Figure 5: Immunohistochemical staining ("IHC") of co-cultures of DRG neurons and oligodendrocytes treated with monoclonal antibodies 1A7 and 2F3 or a control antibody.

Figure 6: A: CC1 antibody staining of mouse oligodendrocytes in the cuprizone model. B. Anti-MBP protein antibody or luxol fast blue staining of cuprizone model mouse neurons. C: Quantification of CC1 antibody-positive oligodendrocytes at weeks 4 and 6.

Figure 7: Surviving RGCs. Anti-Sp35 antibody treatment with monoclonal antibody 1A7 showed significant neuronal survival (80%) in animals treated with 1A7 compared to animals treated with control antibody or PBS, showing only approximately 50% neurons per animal survival rate.